TITLE

COMMENTARY: Sitagliptin improved glycemic control and β-cell function in type 2 diabetes

AUTHOR(S)
Pugh, Jacqueline A.
PUB. DATE
March 2007
SOURCE
ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p39
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article presents the author's views about a study which states that sitagliptin improved glycemic control and ß-cell function in type 2 diabetes. Sitagliptin is a member of the dipeptidyl peptidase-4 inhibitor class of oral agents that block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both of these are released in response to food intake, and both in turn stimulate insulin and suppress glucagon release.
ACCESSION #
24685672

 

Related Articles

  • Safety, tolerability, and nonglycemic effects of incretin-based therapies. Keith Campbell, R.; Cobble, Michael E.; Reid, Timothy S.; Shomali, Mansur E. // Journal of Family Practice;Sep2010 Supplement, Vol. 59, pS20 

    The article focuses on the tolerability, safety, and nonglycemic effects of incretin-based therapies for the treatment of type 2 diabetes mellitus (T2DM). It states that the use of glucose-lowering medications which reduced associated risk factors and indicates favorable safety profile shows...

  • Chronic Administration of Alogliptin (SYR-322), a Novel Dipeptidyl Peptidase-IV Inhibitor, Improved Beta-Cell Function in ob/ob Mice. Moritoh, Yusuke; Takeuchi, Koji; Kataoka, Osamu; Asakawa, Tomoko; Odaka, Hiroyuki // Diabetes;Jun2007 Supplement 1, Vol. 56, pA136 

    Alogliptin (SYR-322) is a novel, oral, potent, and highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under development as a once-daily treatment for type 2 diabetes (T2D). The efficacy of alogliptin was investigated in ob/ob mice, an obese model of T2D. Chronic administration of...

  • Glucagon-like peptide may help weight loss in type 2 diabetes. Siddall, Rhonda // British Journal of Hospital Medicine (17508460);Aug2010, Vol. 71 Issue 8, p428 

    The article offers information on the study of glucagon-like peptide (GLP) analogue for glucose control in diabetic patients. It reports that according to the American Diabetes Association, GLP is also found to better in weight loss than other treatments for diabetes mellitus. It also discusses...

  • Effect of Rosiglitazone Versus Insulin on the Pancreatic β-Cell Function of Subjects With Type 2 Diabetes. Ovalle, Fernando; Bell, David S. H. // Diabetes Care;Nov2004, Vol. 27 Issue 11, p2585 

    OBJECTIVE -- In a previous study, we found observational evidence of improvement in β-cell function when rosiglitazone was added to a failing oral antihyperglycemic regimen consisting of sulfonylureas and metformin. To confirm our previous observations, we designed and performed a...

  • Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes. Vaidya, H. B.; Goyal, R. K. // Current Drug Targets;Oct2008, Vol. 9 Issue 10, p911 

    Diabetes mellitus (DM) has been recognized as a growing world-wide epidemic by many health advocacy groups including the World Health Organization (WHO). DM affects about 6% of the North American population. A recent report estimated that 8.2% of adult population worldwide has impaired glucose...

  • The Prolyl-Aminodipeptidases and their Inhibitors as Therapeutic Targets for Fibrogenic Disorders. Juillerat-Jeanneret, Lucienne; Gerber-Lemaire, Sandrine // Mini Reviews in Medicinal Chemistry;Feb2009, Vol. 9 Issue 2, p215 

    Many biologically active peptides are protected from general proteolytic degradation by evolutionary conserved prolines (Pro), due to conformational constraints imposed by the Pro residue. Thus the biological importance of prolyl-specific peptidases points to a high potential for drug discovery...

  • The use of incretin agents. Aye, Myint Myint; Jennings, Paul // Practice Nursing;Apr2009, Vol. 20 Issue 4, p194 

    The article discusses the role of incretin agents in improving glycaemic control in people with type two diabetes. According to the article, poor glycaemic control is associated with microvascular complications that include nephropathy, retinopathy, and neuropathy. The actions of the incretin...

  • Novel Dipeptidyl Peptidase 8 Transcript, DPP8v-3, Has Catalytic Activity and Is Subject to Inhibition by Inhibitors of DPP-IV and DPP8. Parker, Janice C.; Vanvolkenburg, Maria A.; Robertson, Alan S.; Benbow, John W.; Houseknecht, Karen L.; Hulin, Bernard; Lillquist, Jay S.; Piotrowski, David W.; Soeller, Walter C.; Wright, Stephen W. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA543 

    A large number of pharmaceutical companies are developing inhibitors of the serine protease dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes mellitus. DPPIV inhibitors achieve their euglycemic effects by inhibiting the degradation of the incretin hormone glucagon-like...

  • Preserving beta-cell function in DM2. Kuritzky, Louis // Clinical Oncology Alert;Aug2009 Supplement, p15 

    The article discusses research which investigated the outcome of one-year treatment with exenatide among patients with type 2 diabetes (DM2). It references a study by M. C. Bunck and colleagues published in "Diabetes Care." The trial measured glucose control and beta-cell function (β-CF). The...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics